GNLX Company Profile and Key Details
Genelux Corporation
GNLX Stock Price Chart
Stock Price Today
Genelux Corporation (GNLX) stock surged +9.00%, trading at $3.15 on NASDAQ, up from the previous close of $2.89. The stock opened at $3.07, fluctuating between $3.04 and $3.47 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Company Information
| Employees | 24 |
| Beta | -3.17 |
| Sales or Revenue | $170.00K |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Genelux Corporation (NASDAQ: GNLX) stock price is $3.15 in the last trading session. During the trading session, GNLX stock reached the peak price of $3.47 while $3.04 was the lowest point it dropped to. The percentage change in GNLX stock occurred in the recent session was 9% while the dollar amount for the price change in GNLX stock was $0.26.
The NASDAQ listed GNLX is part of Biotechnology industry that operates in the broader Healthcare sector. Genelux Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Ralph Smalling B.Sc.
Head of Regulatory Affairs
Prof. Paul Scigalla M.D., Ph.D.
Chief Medical Officer
Mr. Thomas Zindrick J.D.
Chairman, Chief Executive Officer & Pres
Ms. Caroline Jewett
Head of Quality
Dr. Joseph Cappello Ph.D.
Chief Technical Officer
Dr. Yong Yu Ph.D.
Senior Vice President of Clinical Devel.
Mr. Sean Ryder J.D.
Gen. Counsel & Corporation Sec.
GNLX's closing price is 80.62% higher than its 52-week low of $1.60 where as its distance from 52-week high of $12.12 is -76.16%.
Number of GNLX employees currently stands at 24.
Official Website of GNLX is: https://www.genelux.com
GNLX could be contacted at phone 858 483 0024 and can also be accessed through its website. GNLX operates from 2625 Townsgate Road, Westlake Village, CA 91361, United States.
GNLX stock volume for the day was 348.38K shares. The average number of GNLX shares traded daily for last 3 months was 156.27K.
The market value of GNLX currently stands at $108.80M with its latest stock price at $3.15 and 34.54M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com